CERUS CORP (CERS)
US1570851014 - Common Stock
We assign a fundamental rating of 2 out of 10 to CERS. CERS was compared to 188 industry peers in the Health Care Equipment & Supplies industry. CERS has a bad profitability rating. Also its financial health evaluation is rather negative. CERS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CERS had negative earnings in the past year.
CERS had a negative operating cash flow in the past year.
CERS had negative earnings in each of the past 5 years.
In the past 5 years CERS always reported negative operating cash flow.
1.2 Ratios
CERS has a Return On Assets of -10.41%. This is comparable to the rest of the industry: CERS outperforms 58.29% of its industry peers.
CERS's Return On Equity of -36.88% is in line compared to the rest of the industry. CERS outperforms 54.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.41% | ||
| ROE | -36.88% | ||
| ROIC | N/A |
ROA(3y)-20.5%
ROA(5y)-26.31%
ROE(3y)-66.27%
ROE(5y)-76.24%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CERS has a Gross Margin of 60.52%. This is in the better half of the industry: CERS outperforms 60.43% of its industry peers.
In the last couple of years the Gross Margin of CERS has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for CERS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60.52% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.77%
GM growth 5Y1.4%
2. Health
2.1 Basic Checks
CERS does not have a ROIC to compare to the WACC, probably because it is not profitable.
CERS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CERS has been increased compared to 5 years ago.
The debt/assets ratio for CERS is higher compared to a year ago.
2.2 Solvency
CERS has an Altman-Z score of -5.10. This is a bad value and indicates that CERS is not financially healthy and even has some risk of bankruptcy.
CERS has a worse Altman-Z score (-5.10) than 68.98% of its industry peers.
A Debt/Equity ratio of 1.21 is on the high side and indicates that CERS has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.21, CERS is doing worse than 79.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.21 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.1 |
ROIC/WACCN/A
WACC9.69%
2.3 Liquidity
A Current Ratio of 2.59 indicates that CERS has no problem at all paying its short term obligations.
CERS's Current ratio of 2.59 is in line compared to the rest of the industry. CERS outperforms 46.52% of its industry peers.
CERS has a Quick Ratio of 1.92. This is a normal value and indicates that CERS is financially healthy and should not expect problems in meeting its short term obligations.
CERS has a Quick ratio (1.92) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.59 | ||
| Quick Ratio | 1.92 |
3. Growth
3.1 Past
CERS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.69%, which is quite impressive.
CERS shows a small growth in Revenue. In the last year, the Revenue has grown by 7.11%.
The Revenue has been growing by 19.67% on average over the past years. This is quite good.
EPS 1Y (TTM)57.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)7.11%
Revenue growth 3Y17.82%
Revenue growth 5Y19.67%
Sales Q2Q%15.7%
3.2 Future
The Earnings Per Share is expected to grow by 22.52% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 12.29% on average over the next years. This is quite good.
EPS Next Y39.16%
EPS Next 2Y26.39%
EPS Next 3Y22.52%
EPS Next 5YN/A
Revenue Next Year18.53%
Revenue Next 2Y14.95%
Revenue Next 3Y12.29%
Revenue Next 5YN/A
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
CERS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CERS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CERS's earnings are expected to grow with 22.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.39%
EPS Next 3Y22.52%
5. Dividend
5.1 Amount
No dividends for CERS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CERUS CORP
NASDAQ:CERS (11/22/2024, 8:00:00 PM)
After market: 1.78 -0.01 (-0.56%)1.79
+0.12 (+7.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap332.44M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.41% | ||
| ROE | -36.88% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60.52% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.21 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.59 | ||
| Quick Ratio | 1.92 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)57.69%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y39.16%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)7.11%
Revenue growth 3Y17.82%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y